
Valeant receives complete response letter from FDA on glaucoma drug
pharmafile | July 22, 2016 | News story | Medical Communications, Sales and Marketing |Â Â FDA, Glaucoma, ValeantÂ
Valeant Pharmaceuticals has announced that it has received a complete response letter from the FDA rejecting their new drug application for latanoprostene bunod ophthalmic solution, an intraocular pressure lowering single-agent eye drop for patients with open angle glaucoma or ocular hypertension.
The FDA raised concerns around the treatment, developed by Valeant subsidiary Bausch + Lomb, after some deficiencies in current good manufacturing practice were identified during an inspection at their facility in Tampa, Florida.
Valeant indicates that, in the FDA’s letter, no efficacy or safety concerns were identified, nor were any more clinical trials needed, for the approval of the new drug application for latanoprostene bunod ophthalmic solution.
The company will now meet with the regulator to address these concerns and find a way to work out a resolution.
Sean Murray
Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …

FDA approves Moderna’s updated COVID-19 vaccines targeting new variant
The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …






